Cosmos Health Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $COSM in the last 30 days.
See all $COSM insider activity →Cosmos Health Inc. reported preliminary Q3 2026 revenue of $17.4M, up 40% YoY, and 9M revenue of $54.3M, up 19% YoY. The company reaffirmed its full-year 2026 revenue outlook of over $90M, driven by growth across all core segments.
Cosmos Health Inc. (NASDAQ: COSM) reported its portfolio of 15+ proprietary brands and 10 branded generics, sold in 40+ countries. The company targets markets estimated at $946B in 2025, with products in nutraceuticals, infection control, advanced formulations, and skin care. Key brands include Sky Premium Life, C-Scrub, and NOOR, with gross margins over 70%. Manufacturing occurs at GMP-certified facilities in Europe and the U.S.
Cosmos Health Inc. reported that its subsidiary CosmoFarm achieved record Q2 2026 revenue of over $15 million, with an annualized run-rate exceeding $60 million. This marks a 4.3x increase in revenue since the acquisition, with daily-served pharmacies growing 3.6x to 360. The company attributes growth to automation, AI, and strategic acquisitions, aiming for $100 million in annualized revenue.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning COSM (Cosmos Health Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent COSM coverage spans financial news, corporate actions and earnings.
Revenue growth beats prior quarters, reinforcing bullish outlook.
The press release provides a broad strategic update but no immediate catalyst for price movement.
The strong subsidiary performance and raised guidance suggest upside for COSM.
The contract expands revenue visibility and could boost earnings as the division ramps to full capacity.
Potential dilution risk if tokenized financing proceeds, but no immediate share issuance.
AlphAI scores every news story that mentions COSM with an AI model for sentiment and relevance, and aggregates insider trades from Cosmos Health Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cosmos Health Inc. reported preliminary Q3 2026 revenue of $17.4M, up 40% YoY, and 9M revenue of $54.3M, up 19% YoY. The company reaffirmed its full-year 2026 revenue outlook of over $90M, driven by growth across all core segments.
1 min readCosmos Health Inc. (NASDAQ: COSM) reported its portfolio of 15+ proprietary brands and 10 branded generics, sold in 40+ countries. The company targets markets estimated at $946B in 2025, with products in nutraceuticals, infection control, advanced formulations, and skin care. Key brands include Sky Premium Life, C-Scrub, and NOOR, with gross margins over 70%. Manufacturing occurs at GMP-certified facilities in Europe and the U.S.
3 min readCosmos Health Inc. reported that its subsidiary CosmoFarm achieved record Q2 2026 revenue of over $15 million, with an annualized run-rate exceeding $60 million. This marks a 4.3x increase in revenue since the acquisition, with daily-served pharmacies growing 3.6x to 360. The company attributes growth to automation, AI, and strategic acquisitions, aiming for $100 million in annualized revenue.
2 min readCosmos Health Inc. (NASDAQ: COSM) announced that its subsidiary, Cana Laboratories, secured five-year agreements with Target Pharma for 5.2 million units, increasing its orderbook to 32.7 million units, a 31% rise since June. The deals cover dermatology and anti-infective products, expanding Cana's therapeutic categories to 11. The company expects the division to generate over $10 million in annual profit at full capacity.
2 min readCosmos Health Inc. (COSM) has engaged Prime Ledger Inc. to structure a tokenized financing for its CCX0722 weight management device, aiming to raise capital without issuing common stock. The company acquired the technology in June 2026 and expects to retain future cash flows. The initial structuring phase is targeted for completion in Q4 2026, but there is no guarantee the financing will be completed.
1 min readCosmos Health (COSM) plans a non-dilutive, tokenized financing for CCX0722, a weight-management device, without issuing new shares. The company owns the IP and targets a $562B market by 2033. Financing details are not yet finalized.
2 min readCosmos Health Inc. (NASDAQ: COSM) announced a new five-year contract with Viofar for manufacturing 2.5 million units of ROSARTIA, a cardiovascular drug. This increases Cana Laboratories' orderbook to 27.5 million units, enhancing cash flow visibility and expanding its manufacturing portfolio. The agreement strengthens Cosmos Health's position in cardiovascular pharmaceuticals.
2 min readCosmos Health Inc. (NASDAQ:COSM) launched C-ScrubVet, an antimicrobial cleanser for animals, in the UK, targeting the $69 billion global animal health market. The product is certified under European standards and manufactured in-house. The company expects this to support its 2029 revenue guidance of $200.6 million, with expansion into additional European markets planned for Q4 2026.
2 min readSOC, HTZ, and COSM stocks fell to 52-week lows. SOC dropped 56% after a $450M offering plan. HTZ declined 1.5% due to price target cuts. COSM initially fell but closed up 5.54% after a $5M share buyback plan. SOC and HTZ have declined 73% and 56% this year, respectively, while COSM is down 64.48%.
2 min readCosmos Health Inc. (NASDAQ: COSM) retired an $8M convertible note a year early, reducing debt and eliminating dilution. The company reported a 30% reduction in operating cash requirements and announced a $5M share repurchase program. Management highlighted record revenue growth and a strong liquidity position, including Bitcoin holdings in a gain position.
2 min read
